Janus kinase Inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Janus kinase Inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?

Published:2012-03-29 Issue:4 Volume:157 Page:426-437
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Harrison Claire¹,Verstovsek Srdan²,McMullin Mary F.³,Mesa Ruben⁴

Affiliation:

1. Department of Haematology; Guy's and St Thomas' NHS Foundation Trust; London; UK

2. Department of Leukemia; MD Anderson Cancer Center, University of Texas; Houston; TX, USA

3. Department of Haematology, CCRCB; Queen's University Hospital; Belfast; UK

4. Division of Hematology and Oncology; Mayo Clinic; Scottsdale; AZ; USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2012.09108.x/fullpdf

Reference65 articles.

1. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology;Aaronson;Journal of the National Cancer Institute,1993

2. Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805;Baffert;Molecular Cancer Therapeutics,2010

3. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet;Barbui;Journal of Clinical Oncology,2011

4. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference;Barosi;Blood,2009

5. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders;Baxter;Lancet,2005

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAK/STAT proteins and their biological impact on NK cell development and function;Molecular Immunology;2019-11

2. Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases;Oncotarget;2017-10-23

3. Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib;Expert Review of Hematology;2017-04-12

4. Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2015-06

5. Rationale for combination therapies in myelofibrosis;Novel Insights into Myelofibrosis Pathophysiology and Treatment;2015-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3